New data show Spiolto® Respimat® provides meaningful quality of life improvements in COPD

  • OTEMTO® trials show Spiolto Respimat provides clinically meaningful >4 point reduction in SGRQ score compared to placebo
  • These results demonstrate that Spiolto Respimat can bring noticeable benefits to the daily life of COPD patients

Spiolto<sup>®</sup> Respimat<sup>®</sup>
Spiolto® Respimat®

Ingelheim, Germany, 17th August 2015 — Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto® Respimat® (tiotropium/olodaterol) provides consistent, clinically meaningful improvements in quality of life versus placebo in patients with COPD*. These data are published online in the journal Respiratory Medicine.1

For COPD patients, breathlessness, among other symptoms, limits their ability to keep active and has a negative impact on their daily lives. As there is no cure for COPD, improving quality of life is a major goal of treatment. In COPD, quality of life is measured using the SGRQ†; a reduction in SGRQ score of 4 points or more is deemed clinically meaningful.2 The OTEMTO® trials show Spiolto® Respimat® provides a reduction in SGRQ total score of 4.67‡ versus placebo.

“The improvement in quality of life provided by Spiolto® Respimat® in these trials could make a noticeable difference to the daily activity of COPD patients and enable them to maintain a more independent life,” said Dave Singh, Professor of clinical pharmacology and respiratory medicine, University of Manchester and lead investigator of the OTEMTO® trials. “For example, this could mean that patients are able to walk up stairs without stopping, go out to socialise with friends or find it easier to wash and dress. Essentially, the data show that patients feel much better.”
Further data from the 1,600 patient OTEMTO® trials show Spiolto® Respimat® provides:

  • clinically meaningful improvements in breathlessness compared to placebo (measured by a 1.62 point improvement in TDI focal score§), reflecting the meaningful quality of life benefits
  • consistent improvements in lung function, breathlessness and quality of life compared to Spiriva® (tiotropium)
  • a safety profile similar to Spiriva® or placebo. Incidence of adverse events (AEs) was broadly similar across treatment groups, with a higher incidence of AEs leading to discontinuation in the placebo groups compared to the treatment groups

OTEMTO® 1&2 build on the pivotal phase III TONADO® trials that demonstrated Spiolto® Respimat® provides significant improvements in lung function, breathlessness, quality of life and reduction in rescue medication use over Spiriva® Respimat® right from the initial disease stages when patients first need maintenance therapy.3,4 OTEMTO® 1&2 are part of the >15,000 patient TOviTO® Phase III clinical trial programme, one of the largest trial programmes conducted in COPD.

U.S. Food and Drug Administration (FDA) recently accepted for review a Supplemental New Drug Application (sNDA) to include the OTEMTO® quality of life data in the Stiolto™ Respimat®** label.
OTEMTO® Respiratory Medicine publication: http://dx.doi.org/10.1016/j.rmed.2015.08.002

Notes to Editors

About Spiolto® Respimat®
To date, Spiolto® Respimat® has gained approval in more than 20 EU/EEA countries, the US, Canada and Australia for use in the treatment of patients with COPD.

Spiolto® Respimat® is built on tiotropium, the active ingredient in Spiriva® - the world’s most prescribed COPD maintenance treatment with over 40 million patient years of real life experience across all COPD severities.5 It is enhanced by olodaterol††, a unique and effective long-acting beta2-agonist with a fast onset of action,6 specifically designed to complement the efficacy of Spiriva®. Spiolto® is delivered by Respimat®, the only inhaler available that actively‡‡ delivers a unique mist, meaning the patient just needs to breathe in naturally for the medication to go deep into the lungs.7-13

About COPD
COPD is a chronic, progressive, treatable, but incurable lung disease that affects 210 million people worldwide.14 It is a growing world health priority and the World Health Organization predicts it will become the 3rd leading cause of death by 2030.15

For people with COPD, decreasing lung function causes breathlessness and stops them from being active. This can lead to a downward spiral of worsening symptoms and even further inactivity,16 contributing to an increased risk of disability and death.17

When the majority of patients first go to see their doctor, their disease has already progressed18 to a point when they need maintenance treatment.19 For most patients at this point§§, lung function is declining at its fastest rate – quicker than in the later stages of the disease.20 Optimal management right from the start of maintenance therapy may give patients the best opportunity to manage their symptoms, stay active and maintain a good quality of life for as long as possible.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit www.boehringer-ingelheim.com

Intended audiences
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Footnotes

* Chronic obstructive pulmonary disease

† St George’s Respiratory Questionnaire (SGRQ), a disease-specific patient-reported instrument that evaluates symptoms including frequency and duration of cough, wheezing and breathlessness

‡ SGRQ total score after 12 weeks of treatment in the combined data set of the 2 replicate studies OTEMTO®1 and OTEMTO® 2

§ Transition dyspnoea index focal score after 12 weeks of treatment in the combined data set

** Spiolto® Respimat® is marketed as Stiolto™ Respimat® in the US and Inspiolto™ Respimat® in Canada

†† Marketed as Striverdi® Respimat®

‡‡ Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation

§§ patients with GOLD 2 COPD

Referências

  1. Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium+olodaterol shows clinically meaningful improvements in quality of life. Res Med 2015 DOI: http://dx.doi.org/10.1016/j.rmed.2015.08.002
  2. Jones PW. St George’s Respiratory Questionnaire: MCID. COPD 2005; 2(1):75-9.
  3. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD2-4). Eur Respir J 2015; 45(4):969-79.
  4. Ferguson GT, Flezar M, Korn S, et al. Efficacy of tiotropium + olodaterol in patients with COPD by initial disease severity and treatment intensity. Adv Ther 2015; 32(6): 523–36.
  5. BI data on file.
  6. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629-45.
  7. Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: Comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest 1998;113:957-63.
  8. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist Inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005;18(3):264-72.
  9. Peterson JB, Prisk GK, Darquenne C. Aerosol deposition in the human lung periphery is increased by reduced-density gas breathing. J Aerosol Med Pulm Drug Deliv. 2008; 21(2):159–68.
  10.  Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 2004;283:1-9.
  11. Zierenberg B. Optimising the in vitro performance of the Respimat. J Aerosol Med 1999;12 (Suppl 1): S19-24.
  12. Dalby RN, Eicher J, Zierenberg B. Development of Respimat SoftMist inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl) 2011;4:145-55.
  13. Anderson P. Use of Respimat Soft Mist Inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3): 251–9.
  14. WHO. Global Alliance Against Chronic Respiratory Diseases. Chronic Respiratory Diseases. http://www.who.int/gard/publications/chronic_respiratory_diseases.pdf [Last accessed Aug 2015]
  15. WHO. Chronic respiratory diseases, Burden of COPD. http://www.who.int/respiratory/copd/burden/en/index.html.
  16. Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med 2006; 119(10 Suppl 1):32-7.
  17. Casaburi R. Activity promotion: a paradigm shift for chronic obstructive pulmonary disease therapeutics. Am Thorac Soc 2011; 8(4):334-7.
  18. Mapel DW, Dalal AA, Blanchette CM, et al. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J COPD 2011; 6 573–81.
  19. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2015. Available from: http://www.goldcopd.org/ [Last accessed Aug 2015]
  20. Tantucci C, Modina D. Lung function decline in COPD. Int J COPD. 2012; 7:95–9.